The Innovation<\/strong><\/p>\n Current T cell receptor (TCR) therapy requires each dose to be custom-made from a patient’s own T cells\u2014a process taking weeks and costing six figures. Donor-derived alternatives could be manufactured in advance but carry graft-versus-host disease risk.<\/p>\n The UCLA approach starts with cord blood stem cells rather than mature T cells. By introducing the cancer-targeting receptor at the stem cell stage, the cells don’t develop their own natural receptors as they mature\u2014eliminating the need for extra gene editing to prevent attacks on healthy tissue.<\/p>\n “Stem cells are undifferentiated\u2014they’re not yet mature T cells with a fixed receptor already in place,” said co-first author Yichen (John) Zhu. “When we differentiate our engineered stem cells into T cells, essentially all of the resulting cells carry the same receptor and go after the same tumor target.”<\/em><\/span><\/p>\n Dual Attack Mechanism<\/strong><\/p>\n The AlloESO-T cells carry two detection systems:<\/p>\n Engineered TCR targeting NY-ESO-1 protein fragments displayed on tumor cell surfaces<\/p>\n Natural killer cell receptors that detect stress signals many tumor cells display<\/p>\n This backup system addresses antigen escape\u2014when tumor cells lose or hide the target antigen.<\/p>\n “Solid tumors are very diverse,” Zhu said. “Some tumor cells lose or hide the antigen a therapy is designed to find. When that happens, a therapy built around a single target loses its grip. Our stem cell-derived cells still have a second mechanism to kill those tumor cells.”<\/em><\/span><\/p>\n Results<\/strong><\/p>\n In mouse models:<\/p>\n Ovarian cancer: Single dose led to durable tumor control and extended survival; comparison group developed graft-versus-host disease<\/p>\n Melanoma: AlloESO-T cells slowed cancer and delayed return; comparison cells offered only fleeting control<\/p>\n After infusion, AlloESO-T cells multiplied roughly 100-fold, traveled to tumors, and stayed active for weeks while largely sparing healthy organs. Conventionally engineered cells spread through liver and lungs, triggering toxicity.<\/p>\n Scale and Cost<\/strong><\/p>\n “From a small number of cord blood stem cells, we can generate trillions of therapeutic cells\u2014enough for thousands of doses\u2014within about six weeks,” said co-senior author Yanruide (Charlie) Li. “At an estimated $5,000 per dose, this approach would be far more accessible than today’s therapies.”<\/em><\/span><\/p>\n The team plans to scale up through the UCLA Health Center for Advanced Biotherapies, potentially moving toward clinical trials faster than starting from scratch.<\/p>\n![\"\"](\"https:\/\/medscriptum.org\/wp-content\/uploads\/2026\/09\/featured-image_1.jpg\")